---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Plasma kallikrein inhibitors for on-demand treatment"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Plasma kallikrein inhibitors for on-demand treatment. Topics: Sebetralstat: oral on-demand treatment, Sebetralstat: FDA approval date, Sebetralstat: FDA-approved indication, Sebetralstat: dosing and maximum daily dose, and 16 further topics. 20 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/plasma-kallikrein-inhibitors-for-on-demand-treatment"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Plasma kallikrein inhibitors for on-demand treatment

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Plasma Kallikrein Inhibitors for On-demand Treatment

<a id="topic-2.2.2.1.3-1"></a>

### Sebetralstat: oral on-demand treatment

> “EKTERLY is a plasma kallikrein inhibitor that is used for the treatment of acute attacks of hereditary angioedema (HAE)”
> “an oral tablet.”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.3-2"></a>

### Sebetralstat: FDA approval date

> “Approval date: July 03, 2025”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.3-3"></a>

### Sebetralstat: FDA-approved indication

> “EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### Sebetralstat: dosing and maximum daily dose

> “The recommended dosage of EKTERLY is one dose of 600 mg (two tablets) orally at the earliest recognition of an acute HAE attack.”
> “A second dose of 600 mg (two tablets) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur.”
> “Maximum recommended dosage is 1,200 mg (four tablets) in any 24-hour period.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### Sebetralstat: dose modification for CYP3A4 inhibitors and inducers and hepatic impairment

> “Avoid use with strong CYP3A4 inhibitors.”
> “In patients taking moderate CYP3A4 inhibitors, take one dose of 300 mg.”
> “Avoid use with moderate or strong CYP3A4 inducers.”
> “Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C).”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### Sebetralstat: adverse reactions in KONFIDENT

> “The most common adverse reaction (incidence ≥2%) is headache.”
> “Adverse Reaction EKTERLY 600 mg (N = 93) Placebo (N = 83)a n (%) n (%) Headache 3 (3.2) 1 (1.2)”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### KONFIDENT: design and results as described in the FDA label

> “KONFIDENT employed a 3-way, complete crossover design comparing EKTERLY 600 mg and EKTERLY 300 mg to placebo.”
> “Severe laryngeal attacks were not treated in KONFIDENT.”
> “Although evaluated in KONFIDENT, EKTERLY 300 mg is not a recommended dose for treatment of acute HAE attacks.”
> “A total of 71 out of 93 (76%) patients administered EKTERLY 600 mg and 41 out of 84 (49%) patients administered placebo achieved”
> “The median time to beginning of symptom relief within 12 hours of first dose was 2.0 hours (95% CI: 1.5, 2.8) in patients administered EKTERLY 600 mg.”
> “A total of 46 out of 93 (49%) patients administered EKTERLY 600 mg and 23 out of 84 (27%) patients administered placebo achieved attack resolution within 24 hours.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

### KONFIDENT: published primary and key secondary endpoints

> “A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks.”
> “The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.”
> “The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.”
> “(Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).”

Source: [Riedl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819658/)

<a id="topic-2.2.2.1.3-9"></a>

### Sebetralstat: pooled analysis of the phase 2 and phase 3 trials

> “377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.”
> “Median (interquartile range) time to treatment was 32.5 min (8.0–94.0).”
> “Median time to beginning of symptom relief was 1.6 h (0.8–7.0) and 1.8 h (1.0–4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo.”

Source: [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)

<a id="topic-2.2.2.1.3-10"></a>

### KONFIDENT-S: interim long-term safety and effectiveness

> “This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.”
> “At data cutoff (January 31, 2024), 84 participants (mean age: 35.9 years; 14.3% <18 years; 64.3% female) treated 640 attacks with sebetralstat (84% of total attacks); the median (interquartile range [IQR]) number of attacks per participant was 5 (2-8).”
> “The median (IQR) time from attack onset to treatment was 9 (1-69) minutes.”
> “Treatment-related TEAEs occurred in 8 participants (9.5%); none were serious.”
> “The median time to beginning of symptom relief (allowing for missing data entries between consecutive time points) was 1.68 (0.79-3.89) hours, to reduction in severity 6.57 (1.61 to >12) hours, and to complete attack resolution 21.02 (7.22 to >24) hours.”

Source: [Farkas et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40886933/)

<a id="topic-2.2.2.1.3-11"></a>

### KONFIDENT-S: breakthrough attacks in participants receiving long-term prophylaxis

> “The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).”
> “As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).”
> “Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.1.3-12"></a>

### KONFIDENT-S: laryngeal and abdominal attacks

> “This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916).”
> “At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat.”
> “Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24).”
> “Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks.”

Source: [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12626162/)

<a id="topic-2.2.2.1.3-13"></a>

### Sebetralstat: guideline statement

> “Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study.”
> “The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.3-14"></a>

### Ecallantide: boxed warning for anaphylaxis

> “Anaphylaxis has been reported after administration of KALBITOR.”
> “Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.”
> “Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-15"></a>

### Ecallantide: FDA-approved indication and dosing

> “KALBITOR® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.”
> “The recommended dose of KALBITOR is 30 mg (3 mL), administered subcutaneously in three 10 mg (1 mL) injections.”
> “If an attack persists, an additional dose of 30 mg may be administered within a 24 hour period.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-16"></a>

### Ecallantide: incidence of anaphylaxis in clinical studies

> “In 255 HAE patients treated with intravenous or subcutaneous KALBITOR in clinical studies, 10 patients (4%) experienced anaphylaxis.”
> “For the subgroup of 187 patients treated with subcutaneous KALBITOR, 5 patients (3%) experienced anaphylaxis.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-17"></a>

### EDEMA4 and EDEMA3: design and results as described in the FDA label

> “The safety and efficacy of KALBITOR to treat acute attacks of hereditary angioedema in adolescents and adults were evaluated in 2 randomized, double-blind, placebo-controlled trials (EDEMA4 and EDEMA3) in 168 patients with HAE.”
> “EDEMA4 was a randomized, double-blind, placebo-controlled trial in which 96 patients were randomized 1:1 to receive KALBITOR 30 mg subcutaneous or placebo for acute attacks of HAE.”
> “The primary endpoint was the change from baseline in MSCS score at 4 hours, and the TOS at 4 hours was a key secondary endpoint.”
> “More patients in the placebo group (24/48, 50%) required medical intervention to treat unresolved symptoms within 24 hours compared to the KALBITOR-treated group (16/48, 33%).”
> “In EDEMA3, the primary endpoint was the TOS at 4 hours, and the key secondary efficacy endpoint was the change from baseline in MSCS at 4 hours.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-18"></a>

### Ecallantide compared with placebo: treatment outcome score at 4 hours in the trial funded by Dyax

> “The median treatment outcome score at 4 hours was 50.0 in the ecallantide group and 0.0 in the placebo group (interquartile range [IQR], 0.0 to 100.0 in both groups; P=0.004).”
> “The estimated time to significant improvement was 165 minutes with ecallantide versus more than 240 minutes with placebo (P=0.14).”
> “(Funded by Dyax; ClinicalTrials.gov number, NCT00262080.)”

Source: [Cicardi et al. (2010b)](https://pubmed.ncbi.nlm.nih.gov/20818887/)

<a id="topic-2.2.2.1.3-19"></a>

### Ecallantide compared with placebo: change in mean symptom complex severity score at 4 hours

> “Mean (SD) change from baseline in mean symptom complex severity score 4 hours after dosing was significantly greater with ecallantide use (-0.8 [0.6]) compared with placebo use (-0.4 [0.8]) (P = .01 comparing distributions).”
> “The benefit of ecallantide was apparent within 2 hours after dosing and was maintained through 24 hours after dosing.”

Source: [Levy et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20568386/)

<a id="topic-2.2.2.1.3-20"></a>

### Ecallantide: guideline position as a second-line option

> “However, concerns about a 3%-4% risk of potentially serious hypersensitivity reactions, including anaphylaxis, led the manufacturer to withdraw its application in Europe.”
> “Despite this, it remains approved by the US Food and Drug Administration (FDA) for administration exclusively by healthcare providers in the United States.”
> “We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
